Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

被引:5
|
作者
Zhang, Lijie [1 ,2 ]
Sun, Tao [1 ,2 ]
Sun, Bo [1 ,2 ]
Zhang, Kailu [1 ,2 ]
Zheng, Yuting [1 ,2 ]
Li, Na [1 ,2 ]
Chen, Lei [1 ,2 ]
Zheng, Chuansheng [1 ,2 ]
Liang, Bin [1 ,2 ]
Shi, Heshui [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, 1277 Jiefang Rd, Wuhan 430022, Peoples R China
[2] Hubei Prov Key Lab Mol Imaging, Wuhan 430022, Peoples R China
关键词
Hepatocellular carcinoma; Transarterial chemoembolization; Tyrosine kinase inhibitors; PD-1; inhibitor; C-REACTIVE PROTEIN; NIVOLUMAB; TIME;
D O I
10.1186/s12885-024-11936-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The prognostic significance of the CRAFITY score (CRP and AFP in ImmunoTherapY) has been demonstrated in hepatocellular carcinoma (HCC) patients receiving immunotherapy. The purpose of this study was to investigate the utility and the predictive value of CRAFITY score in HCC after transarterial chemoembolization (TACE) in combination with tyrosine kinase inhibitors (TKIs) and immunotherapy. Materials and methods Data from patients with advanced HCC treated with TACE plus TKIs and PD-1 inhibitor from January 2019 to June 2022 were collected and analyzed retrospectively. Patients with AFP >= 100 ng/mL and those with CRP >= 1 mg/dL were assigned a CRAFITY score of 1 point. Patients were divided into three groups according to their CRAFITY score (CRAFITY-low, 0 points; CRAFITY-intermediate, 1 point; and CRAFITY-high, 2 points). The differences in overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were compared among the three groups. Tumor response was evaluated at 3, 6 and 12 months after the first combination treatment. Risk factors for OS and PFS were assessed. Results A total of 70 patients were included. The patients were assigned CRAFITY scores of 0 points (CRAFITY-low, n = 25 [35.71%]), 1 point (CRAFITY-intermediate, n = 29 [41.42%]), and 2 points (CRAFITY-high, n = 16 [22.81%]). Multivariate analysis showed that lower CRAFITY score was an independent factor for the improved OS (P =.045) and PFS (P <.001). TACE session was also associated with the OS (P =.048) in the multivariate analysis. The CRAFITY-low cohort achieved a higher objective response rate (ORR) at the 3-month evaluation of tumor response. However, there was no significant difference in ORR and disease control rate (DCR) observed at the 6-month follow-up. DCR showed a statistically significant difference among three groups during the 12-month follow-up period. The percentage of patients with protein urea was highest in the CRAFITY-high group. No significance differences were observed in grade >= 3 AEs in three groups. Conclusion The CRAFITY score is simple and could be useful for predicting treatment outcomes, tumor response and AEs of the HCC patients receiving TACE plus TKIs and PD-1 inhibitor therapy.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
    Guo, Yiwan
    Wu, Wenlong
    Sun, Bo
    Guo, Tingting
    Si, Keke
    Zheng, Chuansheng
    Li, Xin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Kong, Mingxin
    Yu, Guangji
    Wang, Song
    Shi, Zhaozhang
    Han, Huihui
    Lin, Yanyan
    Shi, Jutian
    Song, Jinlong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] The safety and efficacy of transarterial chemoembolization (TACE) plus lenvatinib plus programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma
    Zhang, Xiaoyun
    Zhu, Xinrui
    Liu, Chang
    Lu, Wusheng
    Li, Qiu
    Chen, Weixia
    Li, Zhiping
    Lu, Qiang
    Peng, Wei
    Li, Chuan
    Yan, Lvnan
    Yang, Jiayin
    Wen, Tianfu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Jia, Yuntao
    Han, Huihui
    Lin, Yanyan
    Song, Jinlong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] PD-1 inhibitors improve the efficacy of tyrosine kinase inhibitors combined with transcatheter arterial chemoembolization in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis
    Yu, Jiahui
    Li, Yong
    Yang, Yuting
    Guo, Hao
    Chen, Yimiao
    Yi, Pengsheng
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2025,
  • [36] PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
    Xu, Yongkang
    Fu, Shumin
    Shang, Kai
    Zeng, Jiayu
    Mao, Ye
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study
    Zuo, Mengxuan
    Zheng, Guanglei
    Cao, Yuzhe
    Lu, Hailei
    Li, Da
    An, Chao
    Fan, Weijun
    INTERNATIONAL JOURNAL OF SURGERY, 2025, 111 (01) : 104 - 112
  • [38] Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis
    Chen, Yue
    Jia, Luyao
    Li, Yu
    Cui, Wenhao
    Wang, Jukun
    Zhang, Chao
    Bian, Chunjing
    Luo, Tao
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
    Li, Shu-Qun
    Wu, Jun-Yi
    Wu, Jia-Yi
    Xie, Huang
    Zeng, Zhen-Xin
    Fu, Yang -Kai
    Liu, De -Yi
    Li, Han
    Chen, Wei -Zhao
    Huang, Jing-Yao
    Yan, Mao -Lin
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1799 - 1811
  • [40] Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients
    Zhang, Wenwen
    Hu, Bingyang
    Han, Jun
    Wang, Zhanbo
    Ma, Guangyu
    Ye, Huiyi
    Yuan, Jing
    Cao, Junning
    Zhang, Ze
    Shi, Jihang
    Chen, Mingyi
    Wang, Xun
    Xu, Yinzhe
    Cheng, Yanshuang
    Tian, Lantian
    Wang, Hongguang
    Lu, Shichun
    FRONTIERS IN ONCOLOGY, 2021, 11